Letter: direct-acting anti-viral (DAA) therapy needs strong safety and efficacy check-authors' reply

A W Singer¹, K R Reddy², L E Telep¹, A O Osinusi¹, D M Brainard¹, M Buti³, A P Chokkalingam^{1

4}

Affiliations

¹ Gilead Sciences Inc., Foster City, CA, USA.
² Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
³ Hospital General Universitari Vall d'Hebron, Barcelona, Spain.
⁴ School of Public Health, University of California, Berkeley, CA, USA.

Comment

A W Singer et al. Aliment Pharmacol Ther. 2018 Jul.

. 2018 Jul;48(2):235-236.

doi: 10.1111/apt.14820.

A W Singer¹, K R Reddy², L E Telep¹, A O Osinusi¹, D M Brainard¹, M Buti³, A P Chokkalingam^{1

4}

¹ Gilead Sciences Inc., Foster City, CA, USA.
² Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
³ Hospital General Universitari Vall d'Hebron, Barcelona, Spain.
⁴ School of Public Health, University of California, Berkeley, CA, USA.

No abstract available

Comment on

Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.
Singer AW, Reddy KR, Telep LE, Osinusi AO, Brainard DM, Buti M, Chokkalingam AP. Singer AW, et al. Aliment Pharmacol Ther. 2018 May;47(9):1278-1287. doi: 10.1111/apt.14593. Epub 2018 Mar 7. Aliment Pharmacol Ther. 2018. PMID: 29516535
Letter: direct-acting anti-viral (DAA) therapy needs strong safety and efficacy check.
Mahla RS. Mahla RS. Aliment Pharmacol Ther. 2018 Jul;48(2):233-234. doi: 10.1111/apt.14795. Aliment Pharmacol Ther. 2018. PMID: 29939413 No abstract available.